Literature DB >> 35460023

Osmolality of Excipients for Parenteral Formulation Measured by Freezing Point Depression and Vapor Pressure - A Comparative Analysis.

Mariana Hugo Silva1,2, Sarah P Hudson2, Lidia Tajber3, Matthieu Garin1, Wenyu Dong1, Tatsiana Khamiakova1, René Holm4,5.   

Abstract

PURPOSE: To investigate the difference in methods to determine the osmolality in solutions of stabilizers used for long-acting injectable suspensions.
METHODS: The osmolality was measured by freezing point depression and vapor pressure for 11 different polymers and surfactants (PEG 3350, 4000, 6000, 8000, 20,000, PVP K12, K17 and K30, poloxamer 188, 388 and 407, HPMC E5, Na-CMC, polysorbate 20 and 80, vitamin E-TPGS, phospholipid, DOSS and SDS) in different concentrations.
RESULTS: Independently of the measuring method, an increase in osmolality with increasing concentration was observed for all polymers and surfactants, as would be expected due to the physicochemical origin of the osmolality. No correlation was found between the molecular weight of the polymers and the measured osmolality. The osmolality values were different for PVPs, PEGs, and Na-CMC using the two different measurement methods. The values obtained by the freezing point depression method tended to be similar or higher than the ones provided by vapor pressure, overall showing a significant difference in the osmolality measured by the two investigated methods.
CONCLUSIONS: For lower osmolality values (e.g. surfactants), the choice of the measuring method was not critical, both the freezing point depression and vapor pressure could be used. However, when the formulations contained higher concentrations of excipients and/or thermosensitive excipients, the data suggests that the vapor pressure method would be more suited.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  freezing point depression; osmolality; parenteral vehicles; suspension; vapor pressure

Year:  2022        PMID: 35460023     DOI: 10.1007/s11095-022-03262-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

Review 1.  Injectable long-acting contraceptives.

Authors:  A M Kaunitz
Journal:  Clin Obstet Gynecol       Date:  2001-03       Impact factor: 2.190

2.  Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening.

Authors:  Sudhir Verma; Sumit Kumar; Rajeev Gokhale; Diane J Burgess
Journal:  Int J Pharm       Date:  2010-12-24       Impact factor: 5.875

3.  Long-acting technologies for infectious diseases in LMICs.

Authors:  Lelio Marmora; Carmen Pérez Casas; Ian Grubb; Craig McClure
Journal:  Lancet       Date:  2018-10-24       Impact factor: 79.321

Review 4.  Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics.

Authors:  Julius F Remenar
Journal:  Mol Pharm       Date:  2014-04-30       Impact factor: 4.939

5.  Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

Authors:  Haya Ascher-Svanum; Douglas E Faries; Baojin Zhu; Frank R Ernst; Marvin S Swartz; Jeff W Swanson
Journal:  J Clin Psychiatry       Date:  2006-03       Impact factor: 4.384

Review 6.  Pharmaceutical nanocrystals: production by wet milling and applications.

Authors:  Maria Malamatari; Kevin M G Taylor; Stavros Malamataris; Dennis Douroumis; Kyriakos Kachrimanis
Journal:  Drug Discov Today       Date:  2018-01-08       Impact factor: 7.851

7.  Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.

Authors:  S Swindells; M Siccardi; S E Barrett; D B Olsen; J A Grobler; A T Podany; E Nuermberger; P Kim; C E Barry; A Owen; D Hazuda; C Flexner
Journal:  Int J Tuberc Lung Dis       Date:  2018-02-01       Impact factor: 2.373

Review 8.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Authors:  Andrew Owen; Steve Rannard
Journal:  Adv Drug Deliv Rev       Date:  2016-02-23       Impact factor: 15.470

Review 9.  Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities.

Authors:  Sharon Nachman; Claire L Townsend; Elaine J Abrams; Moherndren Archary; Edmund Capparelli; Polly Clayden; Shahin Lockman; Patrick Jean-Philippe; Kenneth Mayer; Mark Mirochnick; Jane McKenzie-White; Kimberly Struble; Heather Watts; Charles Flexner
Journal:  Lancet HIV       Date:  2019-07-12       Impact factor: 12.767

10.  Ultra-long-acting removable drug delivery system for HIV treatment and prevention.

Authors:  Martina Kovarova; S Rahima Benhabbour; Ivana Massud; Rae Ann Spagnuolo; Brianna Skinner; Caroline E Baker; Craig Sykes; Katie R Mollan; Angela D M Kashuba; J Gerardo García-Lerma; Russell J Mumper; J Victor Garcia
Journal:  Nat Commun       Date:  2018-10-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.